Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
U.S. Patents for Nicox’s Latanoprostene Bunod, Commercialized as VYZULTA®, Eligible for Patent Term Extension

April 22, 2021

View Press Release Corporate presentation Contact us
Previous